KIM II / Hämatologie und Internistische Onkologie / Forschung / Studienzentrale / Aktuell laufende Studien / Hämatologische Neoplasien / MM
|
DSMM XIX |
Phase III |
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma |
|
EMN30 |
Phase III |
Teclistamab + Lenalidomide and Teclistamab Mono versus Lenalidomide Mono in NDMM as Maintenance Therapy Following Autologous Stem Cell Transplantation |